Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Organogenesis Holdings (ORGO) Notes Payables (2017 - 2018)

Organogenesis Holdings has reported Notes Payables over the past 1 years, most recently at $15.9 million for Q4 2018.

For Q4 2018, Notes Payables changed N/A year-over-year to $15.9 million; the TTM value through Dec 2018 reached $15.9 million, changed N/A, while the annual FY2018 figure was $15.9 million, N/A changed from the prior year.
Notes Payables for Q4 2018 was $15.9 million at Organogenesis Holdings.
Over five years, Notes Payables peaked at $15.9 million in Q4 2018 and troughed at $15.9 million in Q4 2018.